Overview

• NICE approved pembrolizumab in combination with carboplatin and paclitaxel for NHS use in England on August 5, 2025.
• Clinical trials underpinning the decision recorded a 26% reduction in mortality risk compared with chemotherapy alone.
• NICE estimates that around 2,100 women with advanced or recurrent endometrial cancer will benefit from the regimen each year.
• The NHS’s Cancer Drugs Fund has moved the treatment into routine care to ensure immediate patient access.
• Under the previous standard therapy, only 15% of stage-four endometrial cancer patients survived for five years.